November 13, 2019
Recently, the first attempt in the United States to use the gene editing tool CRISPR to combat cancer appears to have gone well, according to the initial results of a small human trial to determine safety for the approach. Gene editing is a way to permanently change DNA in order to potentially cure a disease...
November 06, 2019
For the November episode of the Journal Club, Dr. Oliver Medvedik will be reviewing a new study from a team of researchers including Professor George Church. The study saw the deployment of a multiple target gene therapy focused on 3 known longevity genes delivered via an adeno-associated virus. The focus was on mitigating T2 diabetes, heart failure,...
May 08, 2019
In an article last May, we covered how Rejuvenate Bio, a startup biotech company led by Professor George Church, was planning to reverse aging in dogs as a step towards bringing these therapies to us. Those plans are now starting to move forward with news of a trial launch in the fall later this year....
September 06, 2018
Scientists at Stanford University School of Medicine managed to administer effective gene therapy in mice without triggering an autoimmune reaction. The research, led by Dr. Peggy Ho, Ph.D., was published in the Proceedings of the National Academy of Sciences [1]. Study abstract In gene therapy for Duchenne muscular dystrophy there are two potential immunological obstacles....
April 13, 2018
Researchers at Gladstone Institutes in San Francisco report that a gene variant associated with Alzheimer’s works differently in mice and humans, and they also demonstrate how modifying this gene could potentially prevent the plaques associated with Alzheimer’s from forming and damaging the brain. The new study was published in the journal Nature in January 2018 [1]....
March 07, 2018
Some cancer cells express some of the same genes that senescent cells do, so it makes sense that drugs that destroy senescent cells may also destroy cancer cells. This was what the researchers in this new study set out to test. Abstract p16Ink4a is a potent cell cycle inhibitor engaged to support cell cycle arrest...
